<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359979</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-20-7022-OS-CTIL</org_study_id>
    <nct_id>NCT04359979</nct_id>
  </id_info>
  <brief_title>Tamsulosin for Thyroid Lid Retraction</brief_title>
  <official_title>Treatment With Tamsulosin for Upper Eyelid Retraction Related to Thyroid Eye Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effect of using Tamsulosin for treatment of&#xD;
      eyelid retraction as part of thyroid eye disease. The treatment will be offered to all&#xD;
      thyroid patients suffering from eyelid retraction who are treated at the thyroid clinic in&#xD;
      Sheba's Ophthalmology department. All patient will receive information about the drug&#xD;
      Tamsulosin, the possible side effects, and the alternative treatment options for retraction.&#xD;
&#xD;
      Patients recruited will take 0.4mg/day Tamsulosin for 3 months and will have follow-ups at 1&#xD;
      week, 1 month and 3 months to evaluate the retraction status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid eye disease is a common autoimmune disorder caused by antibodies directed against&#xD;
      receptors present in the thyroid cells and extra-ocular muscles and soft tissue of the orbit.&#xD;
      The disorder is characterised by enlargement of the extra-ocular muscles, fatty and&#xD;
      connective tissue volume.&#xD;
&#xD;
      Upper lid retraction is the most common sign of the eye disease (present in up to 92%). The&#xD;
      causes for retraction are not fully understood. It may be related to inflammation of the&#xD;
      Levator muscle and the Muller muscle, or related to over sympathetic activity causing&#xD;
      overstimulation of the Muller muscle.&#xD;
&#xD;
      Upper lid retraction severity can range from very light to severe, with scleral show, eye&#xD;
      dryness and even exposure keratopathy. Additionally it can have a very significant effect on&#xD;
      the patient's appearance (a constant surprised look).&#xD;
&#xD;
      Treatments for lid retraction include aggressive lubrication and tarsorrhaphy if needed&#xD;
      (sewing the eyelids together).&#xD;
&#xD;
      The Muller is a smooth muscle which elevates the upper eyelid and is sympathetically&#xD;
      innervated (alpha receptor).&#xD;
&#xD;
      The drug Tamsulosin which is a selective alpha1 receptor antagonist is commonly used today&#xD;
      for benign prostatic hyperplasia (relaxing the prostate muscle).&#xD;
&#xD;
      In this study we would like to test using Tamsulosin for treatment of lid retraction caused&#xD;
      by thyroid eye disease. We hypothesise that the relaxation of the Muller muscle may have a&#xD;
      beneficial effect on the retraction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>off label use of an approved drug for new indication</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eyelid retraction</measure>
    <time_frame>1 week after starting tamsulosin treatment</time_frame>
    <description>measuring the upper margin to reflex distance (MRD1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eyelid retraction</measure>
    <time_frame>1 month after starting tamsulosin treatment</time_frame>
    <description>measuring the upper margin to reflex distance (MRD1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eyelid retraction</measure>
    <time_frame>3 months after starting tamsulosin treatment</time_frame>
    <description>measuring the upper margin to reflex distance (MRD1)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Thyroid Eye Disease</condition>
  <condition>Eyelid Diseases</condition>
  <arm_group>
    <arm_group_label>tamsulosin treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive 0.4mg/day of Tamsulosin tablet for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>selective alpha1 receptor antagonist</description>
    <arm_group_label>tamsulosin treatment</arm_group_label>
    <other_name>Omnic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Thyroid eye disease patients suffering from upper eyelid retraction in one or both&#xD;
             eyes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant/breastfeeding women&#xD;
&#xD;
          -  previous eyelid surgery/trauma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oded Sagiv, MD</last_name>
    <phone>972542007707</phone>
    <email>Oded.Sagiv@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oded Sagiv, M.D.</last_name>
      <email>oded.sagiv@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Yano S, Hirose M, Nakada T, Nakayama J, Matsuo K, Yamada M. Selective alpha 1A-adrenoceptor stimulation induces Mueller's smooth muscle contraction in an isolated canine upper eyelid preparation. Curr Eye Res. 2010 May;35(5):363-9. doi: 10.3109/02713680903518858.</citation>
    <PMID>20450248</PMID>
  </reference>
  <reference>
    <citation>Kikuchi-Utsumi K, Ishizaka M, Matsumura N, Nakaki T. Alpha(1A)-adrenergic control of piloerection and palpebral fissure width in rats. Auton Neurosci. 2013 Dec;179(1-2):148-50. doi: 10.1016/j.autneu.2013.04.011. Epub 2013 May 20.</citation>
    <PMID>23701912</PMID>
  </reference>
  <reference>
    <citation>Esmaeli-Gutstein B, Hewlett BR, Pashby RC, Oestreicher J, Harvey JT. Distribution of adrenergic receptor subtypes in the retractor muscles of the upper eyelid. Ophthalmic Plast Reconstr Surg. 1999 Mar;15(2):92-9.</citation>
    <PMID>10189635</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Oded Sagiv</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>eyelid retraction</keyword>
  <keyword>tamsulosin</keyword>
  <keyword>alpha receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
    <mesh_term>Eyelid Diseases</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

